Tsha.O

Taysha Gene Therapies maintains a strong liquidity position with $319.8 million in cash and equivalents against total liabilities of $96.4 million. The balance sheet shows total assets of $343.3 million and total equity of $246.9 million, resulting in a conservative debt-to-equity ratio of 0.2. Long-term debt stands at $50.1 million, which is modest relative to the cash hoard. The company trades at a price-to-book ratio of 6.76, reflecting market expectations for future growth despite current unprofitability.

Profitability metrics are deeply negative, with a return on equity of -52.6% and a return on assets of -37.8%. The company reported a net loss of $109.0 million on revenue of $9.8 million, indicating a pre-commercial or early-commercial stage business model typical of biotechnology firms. Operating cash flow was negative $93.1 million, driven by high operating expenses that far exceed the minimal revenue generation. Capital expenditure was negligible at $0.7 million, suggesting that primary cash burn is related to research and development or general administrative costs rather than physical asset acquisition.

Revenue concentration data is not explicitly detailed in segment or geographic breakdowns, but the total revenue of $9.8 million suggests a nascent commercial footprint. The lack of specific segment data implies that revenue may be derived from a single product or a small number of early-stage commercial initiatives. The company’s activity is classified as unclassified within the biotechnology sector, which may reflect a specialized or novel therapeutic area.

Growth trajectory analysis is limited by the absence of historical period data in the input. However, the current financial snapshot indicates a high burn rate relative to cash reserves, with operating cash flow of -$93.1 million against $319.8 million in cash. This suggests a runway of approximately 3-4 years if the burn rate remains constant, though this is a rough estimate given the volatility of biotech cash flows. The high enterprise value to revenue ratio of 187.49 underscores the market’s pricing of future potential rather than current earnings.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary risk lies in the execution of its clinical and commercial strategy, given the significant operating losses and negative cash flow. The low confidence in classification (0.20) may introduce uncertainty in peer comparisons and industry benchmarking.

Recent observations include analyst estimates with a mean price target of $13.15 and a median of $12.00, significantly higher than the current market price of $5.86. The mean recommendation is 1.69, with 4 strong buys and 9 buys, indicating strong analyst optimism. News events show reconciler enqueue activities, which are internal system processes and not material business events.

Revenue $0.00, −100,0% YoY; Operating income −103,0% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −103,0% YoY
• ▍Net income −97,0% YoY
• ▍Free cash flow −95,0% YoY

Revenue $5.5M, +171,3% YoY; Operating income −42,0% YoY.

• ▍Revenue $5.5M, +171,3% YoY
• ▍Operating income −42,0% YoY
• ▍Net income −48,3% YoY
• ▍Free cash flow −50,5% YoY
• ▍Net margin -507.8%

Revenue $0.00, −100,0% YoY; Operating income −31,4% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −31,4% YoY
• ▍Net income −28,2% YoY
• ▍Free cash flow −28,9% YoY

Revenue $2.0M, +78,6% YoY; Operating income −25,6% YoY.

• ▍Revenue $2.0M, +78,6% YoY
• ▍Operating income −25,6% YoY
• ▍Net income −28,4% YoY
• ▍Free cash flow −27,8% YoY
• ▍Net margin -1353.6%

Revenue $2.3M; Operating income -$21.4M.

• ▍Revenue $2.3M
• ▍Operating income -$21.4M
• ▍Net margin -935.2%

Revenue $2.0M; Operating income -$19.9M.

• ▍Revenue $2.0M
• ▍Operating income -$19.9M
• ▍Net margin -929.0%

Revenue $1.8M; Operating income -$25.9M.

• ▍Revenue $1.8M
• ▍Operating income -$25.9M
• ▍Net margin -1427.5%

Revenue $1.1M; Operating income -$21.3M.

• ▍Revenue $1.1M
• ▍Operating income -$21.3M
• ▍Net margin -1882.0%

Revenue $9.8M, +17,3% YoY; Operating income −20,8% YoY.

• ▍Revenue $9.8M, +17,3% YoY
• ▍Operating income −20,8% YoY
• ▍Net income −22,1% YoY
• ▍Free cash flow −22,8% YoY
• ▍Net margin -1115.3%

Revenue $8.3M, −46,1% YoY; Operating income −23,9% YoY.

• ▍Revenue $8.3M, −46,1% YoY
• ▍Operating income −23,9% YoY
• ▍Net income +20,0% YoY
• ▍Free cash flow +22,5% YoY
• ▍Net margin -1071.6%

Revenue $15.5M, +517,5% YoY; Operating income +54,5% YoY.

• ▍Revenue $15.5M, +517,5% YoY
• ▍Operating income +54,5% YoY
• ▍Net income +32,8% YoY
• ▍Free cash flow +38,5% YoY
• ▍Net margin -722.1%

Revenue $2.5M; Operating income +6,2% YoY.

• ▍Revenue $2.5M
• ▍Operating income +6,2% YoY
• ▍Net income +4,9% YoY
• ▍Free cash flow +2,1% YoY
• ▍Net margin -6635.3%